PRVA

PRVA

USD

Privia Health Group Inc. Common Stock

$23.170-0.100 (-0.430%)

Prix en Temps Réel

Healthcare
Health Information Services
États-Unis

Graphique des Prix

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$23.270

Haut

$23.370

Bas

$22.750

Volume

0.01M

Fondamentaux de l'Entreprise

Capitalisation Boursière

2.8B

Industrie

Health Information Services

Pays

United States

Statistiques de Trading

Volume Moyen

0.83M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $15.92Actuel $23.170Haut $26.037

Rapport d'Analyse IA

Dernière mise à jour: 17 avr. 2025
Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

[PRVA: Privia Health Group Inc. Common Stock]: Analyst Buzz & Stock Moves - What's the Story?

Stock Symbol: PRVA Generate Date: 2025-04-17 01:36:19

Alright, let's take a look at Privia Health Group (PRVA). It's a company in the healthcare sector, specifically in health information services. Think of them as helping doctors' offices run more smoothly and efficiently. Recent news and stock price action are giving us some interesting signals.

Recent News Buzz: Analysts are (Mostly) Still Fans

What's the vibe around PRVA in the news? Well, it's generally positive, which is always good to see. We've got a few analyst updates, and the overall message is that these experts still see potential in the stock.

Specifically, Baird just reiterated an "Outperform" rating – that's like saying they think it'll do better than the average stock – and even bumped up their price target to $26. Barclays is a bit more neutral with an "Equal-Weight" rating, but they also raised their price target, to $23. Truist Securities is sticking with a "Buy" rating, though they nudged their price target down a bit to $28. Finally, Needham is firmly in the "Buy" camp, keeping their price target at a solid $30.

So, what does this mean? Basically, the people who spend their days analyzing stocks are still mostly positive on Privia Health. They think the stock price could go up, with targets ranging from $23 to $30. It's not a unanimous cheer, but definitely leaning optimistic.

Price Check: A Bit of a Rollercoaster Lately

Now, let's peek at what the stock price has actually been doing. Looking back over the last month or so, it's been a bit of a bumpy ride. If you glance at the numbers, you'll see a period in early February where the price was climbing, hitting highs around $25. Then, things cooled off, and it drifted downwards through much of March, hitting lows in the $21-$22 range in early April.

However, it seems like it's been trying to bounce back a bit in April. The last few trading days show the price hovering around $24. The most recent close was $24.19. So, after a dip, it's showing signs of trying to recover.

Interestingly, AI predictions suggest a small bump today and then a more noticeable climb over the next couple of days. They're forecasting a few percentage points of increase.

Outlook & Ideas: Cautiously Optimistic, But Watch Closely

Putting it all together, what's the takeaway? It feels like there's a cautiously optimistic lean for PRVA right now.

Why cautiously optimistic? The analyst news is generally positive, suggesting experts see upside. The AI predictions also point to potential near-term gains. Technically, some indicators are flashing bullish signals, like positive momentum and potential buying pressure. However, the stock price has been quite volatile recently, and some fundamental metrics (like high P/E ratio and lower growth) raise questions about valuation.

Potential Entry Consideration: If you're thinking about getting in, the current price range around $24 might be an area to watch. It's near a potential support level, and if the predicted upward trend plays out, it could be a decent entry point. But, and this is important, consider waiting for a bit of confirmation – maybe see if it holds above $24 and shows further upward momentum.

Potential Exit/Stop-Loss Consideration: On the upside, analyst price targets range up to $30. A more conservative take-profit might be around $25.70 - $26, aligning with some analyst targets and the AI's projected target price. For risk management, a stop-loss could be placed below recent lows, perhaps around $23.50 or even a bit lower, depending on your risk tolerance. This is to protect yourself if the stock decides to resume its downward trend.

Company Context Reminder: Privia Health is in the business of helping healthcare providers operate more efficiently. So, news and trends affecting the healthcare industry in general, and physician practices specifically, are extra relevant for this stock.

In short: PRVA is showing some positive signs, but it's not a slam dunk. Keep an eye on price action, watch for confirmation of the predicted upward movement, and always manage your risk. It could be an interesting short-term trading opportunity, but due diligence is key.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. I am acting as an analyst interpreting publicly available data. Investing in the stock market involves risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Actualités Connexes

Analyst Upgrades

JMP Securities Reiterates Market Outperform on Privia Health Gr, Maintains $29 Price Target

JMP Securities analyst Constantine Davides reiterates Privia Health Gr with a Market Outperform and maintains $29 price target.

Voir plus
JMP Securities Reiterates Market Outperform on Privia Health Gr, Maintains $29 Price Target
Analyst Upgrades

Baird Maintains Outperform on Privia Health Gr, Raises Price Target to $26

Baird analyst Michael Ha maintains Privia Health Gr with a Outperform and raises the price target from $24 to $26.

Voir plus
Baird Maintains Outperform on Privia Health Gr, Raises Price Target to $26
Analyst Upgrades

Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23

Barclays analyst Andrew Mok maintains Privia Health Gr with a Equal-Weight and raises the price target from $21 to $23.

Voir plus
Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23
Analyst Upgrades

Truist Securities Maintains Buy on Privia Health Gr, Lowers Price Target to $28

Truist Securities analyst Jailendra Singh maintains Privia Health Gr with a Buy and lowers the price target from $27 to $28.

Voir plus
Truist Securities Maintains Buy on Privia Health Gr, Lowers Price Target to $28
Analyst Upgrades

Needham Reiterates Buy on Privia Health Gr, Maintains $30 Price Target

Needham analyst Matthew Sheerin reiterates Privia Health Gr with a Buy and maintains $30 price target.

Voir plus
Needham Reiterates Buy on Privia Health Gr, Maintains $30 Price Target

Prédiction IABeta

Recommandation IA

Haussier

Mis à jour le: 28 avr. 2025, 14:56

BaissierNeutreHaussier

67.5% Confiance

Risque et Trading

Niveau de Risque3/5
Risque Moyen
Adapté Pour
Modéré
Guide de Trading

Point d'Entrée

$23.19

Prise de Bénéfices

$24.59

Stop Loss

$20.86

Facteurs Clés

Le PDI 5.7 est au-dessus du MDI 4.2 avec un ADX de 17.7, suggérant une tendance haussière
Le cours actuel est extrêmement proche du niveau de support ($23.15), suggérant une forte opportunité d'achat
Le volume de transactions est 5.1x la moyenne (8,635), indiquant une pression d'achat extrêmement forte
Le MACD 0.0228 est en dessous de la ligne de signal 0.0279, indiquant un croisement baissier

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.